skip to main content
US FlagAn official website of the United States government
dot gov icon
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
https lock icon
Secure .gov websites use HTTPS
A lock ( lock ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Explore Research Products in the PAR
It may take a few hours for recently added research products to appear in PAR search results.


Title: Parallel evolution of reduced cancer risk and tumor suppressor duplications in Xenarthra
The risk of developing cancer is correlated with body size and lifespan within species, but there is no correlation between cancer and either body size or lifespan between species indicating that large, long-lived species have evolved enhanced cancer protection mechanisms. Previously we showed that several large bodied Afrotherian lineages evolved reduced intrinsic cancer risk, particularly elephants and their extinct relatives ( Proboscideans ), coincident with pervasive duplication of tumor suppressor genes (Vazquez and Lynch, 2021). Unexpectedly, we also found that Xenarthrans (sloths, armadillos, and anteaters) evolved very low intrinsic cancer risk. Here, we show that: (1) several Xenarthran lineages independently evolved large bodies, long lifespans, and reduced intrinsic cancer risk; (2) the reduced cancer risk in the stem lineages of Xenarthra and Pilosa coincided with bursts of tumor suppressor gene duplications; (3) cells from sloths proliferate extremely slowly while Xenarthran cells induce apoptosis at very low doses of DNA damaging agents; and (4) the prevalence of cancer is extremely low Xenarthrans , and cancer is nearly absent from armadillos. These data implicate the duplication of tumor suppressor genes in the evolution of remarkably large body sizes and decreased cancer risk in Xenarthrans and suggest they are a remarkably cancer-resistant group of mammals.  more » « less
Award ID(s):
2028458
PAR ID:
10397312
Author(s) / Creator(s):
; ; ; ; ;
Date Published:
Journal Name:
eLife
Volume:
11
ISSN:
2050-084X
Format(s):
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. ; ; ; (, Molecular Biology and Evolution)
    Yeager, Meredith (Ed.)
    Abstract Cancer is a disease of multicellularity, observed across the tree of life. In principle, animals with larger body sizes and longer lifespans should be at increased risk of developing cancer. However, there is no strong relationship between these traits and cancer across mammals. Previous studies have proposed that increased copy number of cancer-related genes may enhance the robustness of cancer suppression pathways in long-lived mammals, but these studies have not extended beyond known cancer-related genes. In this study, we conducted a phylogenetic generalized least squares analysis to test for associations between copy number of all protein-coding genes and longevity, body size, and cancer prevalence across 94 species of mammals. In addition to investigating the copy number of individual genes, we tested sets of related genes for a relationship between the aggregated gene copy number of the set and these traits. We did not find strong evidence to support the hypothesis that adaptive changes in gene copy number contribute to the lack of correlation between cancer prevalence and body size or lifespan. However, we found several biological processes where aggregate copy number was associated with malignancy rate. The strongest association was for the gene set relating to transforming growth factor beta, a cytokine that plays a role in cancer progression. Overall, this study provides a comprehensive evaluation of the role of gene copy number in adaptation to body size and lifespan and sheds light on the contribution of gene copy number to variation in cancer prevalence across mammals. 
    more » « less
  2. ; ; ; ; ; ; (, Science Advances)
    null (Ed.)
    Data-driven discovery of cancer driver genes, including tumor suppressor genes (TSGs) and oncogenes (OGs), is imperative for cancer prevention, diagnosis, and treatment. Although epigenetic alterations are important for tumor initiation and progression, most known driver genes were identified based on genetic alterations alone. Here, we developed an algorithm, DORGE (Discovery of Oncogenes and tumor suppressoR genes using Genetic and Epigenetic features), to identify TSGs and OGs by integrating comprehensive genetic and epigenetic data. DORGE identified histone modifications as strong predictors for TSGs, and it found missense mutations, super enhancers, and methylation differences as strong predictors for OGs. We extensively validated DORGE-predicted cancer driver genes using independent functional genomics data. We also found that DORGE-predicted dual-functional genes (both TSGs and OGs) are enriched at hubs in protein-protein interaction and drug-gene networks. Overall, our study has deepened the understanding of epigenetic mechanisms in tumorigenesis and revealed previously undetected cancer driver genes. 
    more » « less
  3. ; ; ; ; ; ; ; ; ; ; et al (, Molecular Biology of the Cell)
    Weaver, Valerie Marie (Ed.)
    Chromosome numbers often change dynamically in tumors and cultured cells, which complicates therapy as well as understanding genotype-mechanotype relationships. Here we use a live-cell “ChReporter” method to identify cells with a single chromosomal loss in efforts to better understand differences in cell shape, motility, and growth. We focus on a standard cancer line and first show clonal populations that retain the ChReporter exhibit large differences in cell and nuclear morphology as well as motility. Phenotype metrics follow simple rules, including migratory persistence scaling with speed, and cytoskeletal differences are evident from drug responses, imaging, and single-cell RNA sequencing. However, mechanotype–genotype relationships between fluorescent ChReporter-positive clones proved complex and motivated comparisons of clones that differ only in loss or retention of a Chromosome-5 ChReporter. When lost, fluorescence-null cells show low expression of Chromosome-5 genes, including a key tumor suppressor APC that regulates microtubules and proliferation. Colonies are compact, nuclei are rounded, and cells proliferate more, with drug results implicating APC, and patient survival data indicating an association in multiple tumor-types. Visual identification of genotype with ChReporters can thus help clarify mechanotype and mechano-evolution. 
    more » « less
  4. ; ; ; ; ; ; ; ; ; ; et al (, Journal of advanced technological education)
    Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. The underlying cause of cancer relates to the cell cycle, during which DNA is replicated. Cancer cells accumulate DNA mutations that help them acquire cancerous features, such as evading cell death and indefinite growth [1]. If these DNA mutations are in coding regions, they are translated to mutated proteins. The epitopes that contain these mutations are called neoantigens. Neoantigens are highly tumor-specific and can be targeted with immunotherapies [2]. During cell division, tumor suppressor genes play a role in the case of DNA damage or replication errors. The p53 protein is a tumor suppressor gene product that prevents tumor formation by activating processes that block cell division when DNA damage has occurred [3]. Mutant p53 does not effectively bind DNA or activate the production of proteins necessary for the stop signal. This project explored a hypothesis that a set of distinct p53 protein mutations can be selected to serve as potential targets for cancer immunotherapy and vaccines by using immunoinformatics predictive analysis tools. By comparing these potential targets with experimental results, we can predict epitopes that may serve as neoantigen targets for immunotherapy. We identified candidate immunogenic epitopes using the NCI’s TP53 Database (NCI DB - tp53.isb-cgc.org), Cancer Epitope Database and Analysis Resource (CEDAR - cedar.iedb.org), and a powerful new bioinformatics tool (nextgen-tools.iedb.org/) [4] hosted by Immune Epitope Database (IEDB - iedb.org) and CEDAR.  Comparing predicted epitopes to highly mutable regions of p53 in tumor variants from NCI DB revealed areas of overlap that may be priority candidate epitopes for immunotherapy.  Experimental data from CEDAR tested the immunogenicity of normal and mutated protein versions to help avoid harmful cross-reactions. These results help predict cancer epitope amino acid sequences relevant to understanding the immune system's role in cancer progression, prevention, and treatment. These studies also set the stage for important subsequent undergraduate research projects to further characterize predicted cancer neoantigens. 
    more » « less
  5. ; ; (, Nano research applications)
    Nanoparticles have been widely used as remedies for disorders for a long time. They are 10-9 m specks of substances that can be found both naturally and synthesized in the laboratory with metal and nonmetal materials. In this study, gold nanoparticles (AuNPs) were synthesized using the citrate reduction method, and the 35 nm size of the nanoparticles was determined using a UV-Vis Spectrophotometer at 525 nm wavelength. The synthesized nanoparticles were further studied on MCF-7 breast cancer cells to understand how various genes are expressed in the induction of apoptosis in signal transduction pathways. The results obtained from the anticancer activity of the gold nanoparticles showed approximately 90% inhibition of cell growth after 72 hours of treatment. Western blot analysis demonstrated the downregulation of p44/42 MAPK (ERK1/2) protein due to gold nanoparticle treatment. Moreover, reverse transcription-polymerase chain reaction (RT-PCR) analysis of apoptotic genes revealed the upregulation of the p53 tumor suppressor gene, Bax, and caspase-9. The results assembled from this study further indicates that p44/42 MAPK, p53, caspase 9 and Bax play a major role in the mechanism of apoptosis in the MCF-7 breast cancer cells. 
    more » « less
  • Citation Formats
  • MLA
  • APA
  • Chicago
  • BibTeX
  • Save / Share this Record
  • Send to Email